Trkb Modulators For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Tropomyosin Receptor Kinase B (TrkB) is the high-affinity receptor for Brain-Derived Neurotrophic Factor (BDNF) and plays a critical role in neuronal survival, synaptic plasticity, and cognitive function. TrkB modulators represent an emerging therapeutic strategy for neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.
TrkB (encoded by the NTRK2 gene) is a receptor tyrosine kinase that activates downstream signaling pathways upon BDNF binding:
In neurodegenerative diseases, BDNF/TrkB signaling is often downregulated:
| Drug | Company | Stage | Indication |
|---|---|---|---|
| 7,8-DHF | Various | Preclinical | AD, PD |
| R13 | --- | Preclinical | Neuroprotection |
| BT44 | --- | Preclinical | PD |
TrkB activation may:
TrkB modulators may:
TrkB activation may:
The study of Trkb Modulators For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Huang EJ, Reichardt LF. TrkB: a novel therapeutic target for neurodegenerative disorders? Neurobiol Aging. 2003;24(7):937-943.
[2] Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nature. 2011;477(7364):350-358.
[3] Liu X, et al. Small molecule TrkB agonists promote neurite outgrowth and protect against amyloid-beta toxicity. ACS Chem Neurosci. 2019;10(7):3119-3130.
[4] Devi L, Ohno M. TrkB signaling is required for behavioral benefits of BDNF/TrkB upregulation in Alzheimer's disease. Neurobiol Dis. 2014;62:191-199.
[5] Baydyuk M, Xu B. BDNF signaling and surmounting obstacles to CNS drug delivery. J Neurochem. 2020;155(1):4-19.
[6] Zhou J, et al. TrkB activation by 7,8-dihydroxyflavone provides therapeutic benefits in models of Parkinson's disease. Sci Rep. 2016;6:31035.
[7] Xie Y, et al. TrkB protein agonists as potential therapeutic agents for neurological disorders. Expert Opin Ther Pat. 2020;30(11):807-820.
[8] Liu X, et al. TrkB agonist-loaded nanoparticles for targeted delivery to the brain. Nat Commun. 2022;13(1):4215.